Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 5/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 4/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.43 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8139092 | 0.85 | VCAM1 (0.46) | S1PR3CASP1ARPARP1BCAT2 | |
| SCHEMBL17272798 | 0.83 | TSHR (0.59) | S1PR3TRPV4ARS1PR2S1PR1 | |
| SCHEMBL6805165 | 0.82 | AR (0.58) | S1PR3CASP1TRPV4ARADRA1D | |
| SCHEMBL2973768 | 0.82 | PARP15 (0.46) | PARP1CYP11B2PARP15PARP10PARP2 | |
| SCHEMBL5899647 | 0.81 | S1PR3 (0.52) | S1PR3CASP1TRPV4ARIDO1 | |
| SCHEMBL15938751 | 0.79 | PARP15 (0.43) | PARP1CYP11B2PARP15PARP10PARP2 | |
| SCHEMBL27338348 | 0.79 | S1PR3 (0.50) | S1PR3CASP1TRPV4ARIDO1 | |
| SCHEMBL2767509 | 0.78 | S1PR3 (0.50) | S1PR3ARPARP1S1PR2S1PR1 | |
| SCHEMBL7155625 | 0.78 | PARP1 (0.45) | PARP1CYP11B2PARP15PARP10PARP2 | |
| SCHEMBL15464961 | 0.78 | CYP11B2 (0.60) | S1PR3TRPV4PARP1S1PR1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| US-7759390-B2 | chemokine receptor 9(CCR9) antagonists such as, 5-Chloro-thiophene-2-sulfonic acid (4-cyano-2-methyl-phenyl)-amide, used for treating autimmune and inflammatory diseases, transplantat rejection and cancer | NOVARTIS AG (CH) | 2010-07-20 | — | — | US | claimed |
| US-20080300295-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-12-04 | — | — | US | claimed |
| EP-1966182-A1 | INHIBITORS OF CCR9 ACTIVITY | Novartis AG (CH) | 2008-09-10 | — | — | EP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| WO-2007071440-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | disclosed |
| WO-2016053855-A1 | SPHINGOSINE-1-PHOSPATE RECEPTOR MODULATORS FOR TREATMENT OF CARDIOPULMONARY DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-04-07 | — | — | WO | disclosed |
| US-8367667-B2 | Pyrrole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-7759390-B2 | chemokine receptor 9(CCR9) antagonists such as, 5-Chloro-thiophene-2-sulfonic acid (4-cyano-2-methyl-phenyl)-amide, used for treating autimmune and inflammatory diseases, transplantat rejection and cancer | NOVARTIS AG (CH) | 2010-07-20 | — | — | US | disclosed |
| EP-1966182-A1 | INHIBITORS OF CCR9 ACTIVITY | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2008077646-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-03 | — | — | WO | disclosed |
| WO-2007071440-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | S1PR3 423/4885CASP1 4017/4885TRPV4 264/4885 |
| US-20080300295-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | S1PR3 456/4885CASP1 268/4885TRPV4 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.